BSD Medical Bolsters U.S. MicroThermX® Support Team with Hiring of Shella Leahy
July 23 2014 - 9:15AM
Business Wire
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD)
(www.BSDMedical.com) today announced that it has hired Shella Leahy
to provide technical, clinical, educational and field support for
its MicroThermX microwave ablation system in the United States. Ms.
Leahy will lead educational and training activities with customers
and sales representatives throughout the United States.
“We continue to make solid inroads in the education, adoption,
and use of our MicroThermX system in the United States,” said Brian
Ferrand, BSD Vice President of Domestic Sales of BSD Medical. “To
that end, it is imperative we make additional key hires to support
our growing base of users. Shella is an exceptional addition to our
team with over fifteen years of medical device experience. She
practiced for many years as a Chief Technologist using equipment
with patients in a hospital environment and more recently worked at
a well-known, multi-billion market cap medical device company
teaching medical device usage at over eighty hospitals, giving her
an excellent foundation from both a customer and sales perspective.
She will play an integral part in supporting our recently announced
distribution agreement efforts in the West with Comed Medical
Specialties.”
Ms. Leahy joins BSD from Hologic, Inc. a maker of premium
diagnostic products, medical imaging systems and surgical products
serving the healthcare needs of women, where she was responsible
for interfacing with hospitals across California to sell and train
them on new diagnostic equipment. Prior to Hologic, she spent more
than a decade in hospital and clinical settings involved in all
aspects of medical imaging.
About the MicroThermX Microwave Ablation
System
The MicroThermX Microwave Ablation System is a compact, mobile,
state-of-the-art, proprietary system that includes a microwave
generator, single-patient-use disposable antennas, and a
thermistor-based temperature monitoring system. The innovative
design of the MicroThermX is the first of its kind that allows
delivery of higher power levels using a single generator. The
MicroThermX utilizes innovative synchronous phased array technology
that was developed and patented by BSD to provide larger and more
uniform zones of ablation during a single procedure. The
MicroThermX product line includes an innovative, high-end
disposable that is used in each ablation treatment, and provides
ongoing revenue streams for BSD. The soft tissue ablation world
market potential is estimated to exceed $2.3 billion. The U.S. Food
and Drug Administration (FDA) has granted the Company a 510(k)
clearance to market the MicroThermX for ablation of soft tissue.
BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX system in Europe. CE marking
is also recognized in many countries outside of the EU, providing
BSD the ability to market the MicroThermX to a number of
international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy, which is delivered using focused radiofrequency (RF) and
microwave energy. BSD’s product lines include both hyperthermia and
ablation treatment systems. BSD’s MicroThermX microwave ablation
system has been developed as a stand-alone therapy to employ
precision-guided microwave energy to ablate (destroy) soft tissue.
The Company has developed extensive intellectual property, multiple
products in the market and established distribution in the United
States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
This press release may be deemed to contain forward-looking
statements, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that these forward-looking statements are only
predictions and may differ materially from actual future events or
results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company
to produce the products to meet the demand, global economic
conditions and uncertainties in the geopolitical environment and
other risk factors set forth in the Company’s most recent reports
on Form 10-K and Form 10-Q. Any forward-looking statements in this
release are based on limited information currently available to the
Company, which is subject to change, and the Company will not
necessarily update the information.
Financial ProfilesTricia Ross,
310-622-8226tross@finprofiles.com